155 related articles for article (PubMed ID: 7963701)
1. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.
McLean CS; Erturk M; Jennings R; Challanain DN; Minson AC; Duncan I; Boursnell ME; Inglis SC
J Infect Dis; 1994 Nov; 170(5):1100-9. PubMed ID: 7963701
[TBL] [Abstract][Full Text] [Related]
2. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.
Boursnell ME; Entwisle C; Blakeley D; Roberts C; Duncan IA; Chisholm SE; Martin GM; Jennings R; Ni Challanaín D; Sobek I; Inglis SC; McLean CS
J Infect Dis; 1997 Jan; 175(1):16-25. PubMed ID: 8985191
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
4. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
6. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
[TBL] [Abstract][Full Text] [Related]
7. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
8. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
9. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.
McLean CS; Ni Challanáin D; Duncan I; Boursnell ME; Jennings R; Inglis SC
Vaccine; 1996 Jul; 14(10):987-92. PubMed ID: 8873393
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
Brans R; Yao F
BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
[TBL] [Abstract][Full Text] [Related]
13. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.
Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D
Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].
Brans R
Hautarzt; 2010 Dec; 61(12):1073-8. PubMed ID: 21052616
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
[TBL] [Abstract][Full Text] [Related]
18. A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.
Fleck M; Podlech J; Weise K; Falke D
Med Microbiol Immunol; 1994 May; 183(2):87-94. PubMed ID: 7935163
[TBL] [Abstract][Full Text] [Related]
19. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
Wachsman M; Kulka M; Smith CC; Aurelian L
Vaccine; 2001 Feb; 19(15-16):1879-90. PubMed ID: 11228357
[TBL] [Abstract][Full Text] [Related]
20. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection.
Bernstein DI
Vaccine; 2000 Jan; 18(14):1351-8. PubMed ID: 10618532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
